It has been reported that many PI3K/Akt/mTOR small molecule inhibitors are widely used in preclinical studies, and some inhibitors, such as idelalisib, duvelisib and deforolimus, have been clinically approved for cancer treatment [26]. Here, AKT1 is linked to cancer.